登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07419867,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Histologically confirmed invasive breast cancer.
入选标准第 3 条
Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s).
入选标准第 16 条
Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment.
排除标准第 5 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
入选标准第 2 条
Hemoglobin (Hb)≥90 g/L;
入选标准第 7 条
Absolute neutrophil count (ANC)≥1.5×10\^9/L;
入选标准第 8 条
Platelet count (PLT)≥100×10\^9/L;
入选标准第 9 条
Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN);
入选标准第 10 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN;
入选标准第 11 条
Alkaline phosphatase (ALP)≤2.5×ULN;
入选标准第 12 条
Serum creatinine (Cr)≤1.5×ULN;
入选标准第 13 条
Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation).
入选标准第 14 条
At least one measurable lesion according to RECIST 1.1.
入选标准第 5 条
Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer.
排除标准第 1 条
Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease.
排除标准第 6 条
Pregnant or breastfeeding.
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07419867,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Female patients aged 18 to 70 years. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Histologically confirmed invasive breast cancer. Known ER, PR and HER2 status. At least one measurable lesion according to RECIST 1.1. Adequate organ function, meeting all of the following: Hemoglobin (Hb)≥90 g/L; Absolute neutrophil count (ANC)≥1.5×10\^9/L; Platelet count (PLT)≥100×10\^9/L; Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN; Alkaline phosphatase (ALP)≤2.5×ULN; Serum creatinine (Cr)≤1.5×ULN; Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation). Left ventricular ejection fraction (LVEF)≥55% at baseline as measured by echocardiography or multi-gated acquisition (MUGA) scan. Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s). The subject voluntarily agrees to participate, signs the informed consent form, has good compliance, and is willing to adhere to follow-up.排除标准:Exclusion Criteria:
Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer. Diabetics or those allergic to radionuclides who are not suitable for 18F-FDG PET/MR examination. Serious cardiovascular or cerebrovascular disease within 6 months prior to randomization, including but not limited to congestive heart failure, unstable angina, severe arrhythmias uncontrolled by medication, severe conduction abnormalities or clinically significant valvular disease, uncontrolled severe hypertension, myocardial infarction, or cerebrovascular accident. Any serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment. Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease. Severe and uncontrolled infection or known HIV infection. Active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment) or fungal infection. Pregnant or breastfeeding. Known allergy to the study drug or any of its excipients, or a history of severe hypersensitivity reactions to other monoclonal antibodies. Known abuse of psychotropic substances, alcoholism, or drug abuse. Known, definite neurological or psychiatric disorders associated with poor compliance, including but not limited to epilepsy or dementia. Any other serious physical or mental illness or laboratory abnormality that may increase the risk of study participation or interfere with study treatment and outcomes, or any other condition that, in the investigator's judgment, makes the patient unsuitable for this study. Receiving radiotherapy (except for palliative reasons), chemotherapy and immunotherapy within 3 weeks before treatment, excluding bisphosphonates (can be used for bone metastasis).
引自 ClinicalTrials.gov, NCT07419867, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07419867,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。